Healthy, smiling middle-aged man happy to be able to address his liver or cardiometabolic disease. Healthy, smiling middle-aged man happy to be able to address his liver or cardiometabolic disease.

Working to Address Liver and Cardiometabolic Diseases with Growing Needs

We are a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. We are driven to help change the dynamic for patients, and through our experience, know that science is key to breaking this cycle of suboptimal treatments.

Our lead candidate, pegozafermin, is an investigational glycopegylated FGF21 analog currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). We believe that targeting FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, may be a promising option for people with liver and cardiometabolic diseases, such as MASH and SHTG.

Leadership

Our leadership team is built to tackle the many nuanced and multi-faceted needs of patients with liver and cardiometabolic diseases. We are well equipped to design and execute clinical development programs, and having created and led fully commercialized companies, we have the expertise to bring this potential new therapy to patients efficiently.

Executive Team

Rohan Palekar Chief Executive Officer
Rohan Palekar
Chief Executive Officer
Hank Mansbach, MD Chief Medical Officer
Hank Mansbach, MD
Chief Medical Officer
Quoc Le-Nguyen Chief Technical Officer
Quoc Le-Nguyen
Chief Technical Officer
Ryan Martins Chief Financial Officer
Ryan Martins
Chief Financial Officer
Teresa Perney, PhD Chief Regulatory and Quality Officer
Teresa Perney, PhD
Chief Regulatory and Quality Officer
Francis Sarena Chief Operating Officer
Francis Sarena
Chief Operating Officer

Management Team

Melissa Abel Senior Vice President, Commercial Strategy
Melissa Abel
Senior Vice President, Commercial Strategy
Michael Baldwin Senior Vice President, Head of Quality
Michael Baldwin
Senior Vice President, Head of Quality
Annie Chang Vice President, Investor Relations and Corporate Communications
Annie Chang
Vice President, Investor Relations and Corporate Communications
Jyoti Chauhan Vice President, Regulatory Affairs
Jyoti Chauhan
Vice President, Regulatory Affairs
Shaji Joseph Vice President, CMC
Shaji Joseph
Vice President, CMC
Amanda Kurihara Vice President, People & Culture
Amanda Kurihara
Vice President, People & Culture
Shiva Natarajan, CPA Senior Vice President, Finance & Principal Accounting Officer
Shiva Natarajan, CPA
Senior Vice President, Finance & Principal Accounting Officer
Paul Shin Senior Vice President, Research & Development Operations
Paul Shin
Senior Vice President, Research & Development Operations
Wenyan Wang, PhD Vice President, Clinical Development
Wenyan Wang, PhD
Vice President, Clinical Development

Board of Directors

Steven Altschuler, MD (Chairman)
Managing Director, Ziff Capital Partners
E. Morrey Atkinson, PhD
Executive Vice President and Chief Technical Operations Officer, Vertex Pharmaceuticals
Martin Babler
President, CEO and Chairman of the Board, Alumis Therapeutics
Derek DiRocco, PhD
Partner, RA Capital Management
Michael Hayden
CM, BC, MBChB, PhD, FRCP(C), FRSC
Kathy LaPorte
Charles A. McWherter, PhD
Rohan Palekar
CEO
Lota Zoth, CPA

Contact Us

For inquiries to request additional information, please select the most appropriate method of communication from the choices below.

General Information
info@89bio.com

Investor Inquiries
investors@89bio.com

Business Development
busdev@89bio.com

Locations

United States

PRIMARY LOCATION

655 Montgomery Street, Suite 1500
San Francisco, CA 94111, US

MAILING ADDRESS

142 Sansome Street, 2nd Floor
San Francisco CA 94104, US

Israel

SATELLITE OFFICE

4 Oppenheimer Street
Rehovot 7670104, Israel